Search
Cilomilast
go.drugbank.com/drugs/DB03849InvestigationalFollowing four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile.
Linaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide is a synthetic 14-amino acid cyclic peptide [A260271] and first-in-class guanylate cyclase-C (G-CC) agonist. … Linaclotide was first approved by the FDA on August 30, 2012.[A260271] It gained EMA and Health Canada approval on November 26, 2012 [L47216] and December 3, 2013,[L47221] respectively.
Synonyms: -GLUTAMYL-L-TYROSYL-L-CYSTEINYL-L-CYSTEINYL-L-ASPARAGINYL-L-PROLYL-L-ALANYL-L-CYSTEINYL-L-THREONYLGLYCYL-L-CYSTEINYL-, CYCLIC (1->6),(2->10),(5->13)-TRIS(DISULFIDE)Neisseria meningitidis serogroup b nada protein antigen
go.drugbank.com/drugs/DB10785ApprovedInvestigationalMixtures: BEXSERO 0,5 ML İM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 10 ADET İĞNESİZ, BEXSERO 0,5 ML İM ENJEKSİYONLUK SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET 2 İĞNELİAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[A254941] However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding … [L43847] In December 2022, the FDA granted accelerated approval to adagrasib for the treatment of KRAS<sup>G12C</sup>-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesLCP-AtorFen
go.drugbank.com/drugs/DB05769Investigational(LDL-C), high density lipoprotein cholesterol (HDL-C) and triglycerides (TG). … LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol levels, addressing three primary cardiovascular risk factors: low density lipoprotein cholesterol
Gamolenic acid
go.drugbank.com/drugs/DB13854ApprovedWithdrawnIt is converted to [DB00154], a biosynthetic precursor of monoenoic prostaglandins such as PGE1. … It is an omega-6 polyunsaturated fatty acid (PUFA) also referred to as 18:3n-6; 6,9,12-octadecatrienoic acid; and cis-6, cis-9, cis-12- octadecatrienoic acid [F27].
Mixtures: Gla 130 Primrose Oil, Bio-efa Borage Gla 90 CapTelisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigationalto be approved for this specific patient population. … [L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsDe Novo Triacylglycerol Biosynthesis TG(16:0/22:4(7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
smpdb.ca/view/SMP0018069MetabolicThe next three steps are localized to the endoplasmic reticulum membrane. … Second, the mitochondrial outer membrane enzyme glycerol-3-phosphate acyltransferase esterifies an acyl-group to the sn-1 position of sn-glycerol 3-phosphate to form 1-acyl-sn-glycerol 3-phosphate (lysophosphatidic
De Novo Triacylglycerol Biosynthesis TG(16:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z))
smpdb.ca/view/SMP0018212MetabolicThe next three steps are localized to the endoplasmic reticulum membrane. … Second, the mitochondrial outer membrane enzyme glycerol-3-phosphate acyltransferase esterifies an acyl-group to the sn-1 position of sn-glycerol 3-phosphate to form 1-acyl-sn-glycerol 3-phosphate (lysophosphatidic
De Novo Triacylglycerol Biosynthesis TG(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:4(7Z,10Z,13Z,16Z))
smpdb.ca/view/SMP0018236MetabolicThe next three steps are localized to the endoplasmic reticulum membrane. … Second, the mitochondrial outer membrane enzyme glycerol-3-phosphate acyltransferase esterifies an acyl-group to the sn-1 position of sn-glycerol 3-phosphate to form 1-acyl-sn-glycerol 3-phosphate (lysophosphatidic